Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

neurology drug discovery

PharmaDeviceNews neurology drug discovery

Congruence Revenir platform moves into neurology and immunology under Ono agreement

Pharma & Biotech

Ono Pharmaceutical strengthens early-stage pipeline with Congruence platform deal

by Pallavi Madhiraju
March 3, 2026
0 Comments

Ono Pharmaceutical expands its Congruence alliance into neurology and immunology. Explore what this means for AI-driven drug discovery and pipeline risk.

Read More

Latest news and features

Innovent just secured seven reimbursement wins in China. Can mazdutide deliver its next growth surge?
Could routine OB/GYN visits become a frontline defence against heart disease? Unified is testing the idea
IMFINZI’s new bladder cancer regimen cut death risk by 42%. Can AstraZeneca win against an approved rival?
Zai Lab just secured reimbursement for two growth medicines. Can 2027 reverse its revenue decline?
Ionis reports 95% fewer HAE attacks after two years. Can DAWNZERA defend its dosing advantage?
Drug testing has been stuck with paper for decades. Did i3collect just change the rules?
Clene cut a six-week ALS data task to one week. Can faster analysis help its $9.9m cash runway?
Evidation captured 1,300 symptom assessments in 60 days. Could blood sampling finally reveal what happens during autoimmune flares?
I2Pure says conventional iodine strength can conceal a delivery problem. What does the chemistry reveal?
Rocket Pharmaceuticals has an approved gene therapy and $279m in cash. Can it deliver on both fronts?
Celanese just sold another 19% of Nutrinova for $152m. Why is Mitsui taking greater control?
Organon’s VTAMA achieved up to 70% EASI75 response in one eczema subgroup. How broadly do the results apply?

POPULAR NEWS

plated Skin Science’s new BODY Serum brings platelet-derived exosome skincare beyond the face, targeting signs of aging, texture and hydration across the body. Representative image.

Pharma & Biotech

Rion Aesthetics expands plated Skin Science exosome platform with $338 BODY Serum

August 19, 2026

Pharma & Biotech

Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?

October 27, 2026

Medical Devices & Diagnostics

Presage Technologies SmartSpectra cleared for contactless vital signs monitoring

July 8, 2026

Latest business and industry news

Grasim reports Rs 234cr loss despite Rs 50,105cr revenue as paint business expands
Can Innovent’s dual-target IAR177 antibody overcome the limitations of existing rheumatoid arthritis treatments?
From forestry waste to AI power: Can Lewis County turn US$1.4m in grants into a bankable energy campus?
China’s nuclear expo is targeting 150,000 visitors. What does it reveal about the next investment cycle?
Southwest Airlines just streamed live gaming at 35,000 feet. Could better Wi-Fi change passenger loyalty?

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration US Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.